Videos
ODYSSEY FHI FHII
Fewer than 80% of familial hypercholesterolaemia (FH) patients achieved an LDL-C level of
read more »
ODYSSEY trials at ESC Congress Hotline
ESC Congress 2014: Lipids Hotline: ODYSSEY TRIALS Prof Alberto Zambon, University of Padua, Italy discusses the four ODYSSEY trials with the PCSK9 inhibitor alirocumab presented at ESC Congress Hotline Sunday. Addition of a new investigational agent – Alirocumab – to high doses of statins result…
read more »
Implications from TESLA and early TAUSSIG studies with evolocumab
Results of clinical trials of the investigational therapy – evolocumab, a PCSK9 inhibitor will potentially change care of patients at a high risk of cardiovascular disease (heart attacks), by reducing their very high low density lipoprotein cholesterol (LDL-C) levels. The Forum talks to Professor Gerald…
read more »
FH issues in low to middle income regions
Despite the availability of statins, treatment of familial hypercholesterolaemia (FH) is a significant issue with a high unmet need in a middle-income country, according to Dr Dirk Blom of Cape Town, South Africa. As a result, new novel therapies are urgently needed.
read more »
Rationale for TESLA and results
Low density lipoprotein cholesterol (LDL-C) can be significantly reduced in patients with a serious genetic disorder – homozygous familial hypercholesterolaemia (FH) – when a PCSK9 inhibitor evolocumab is added to statins and other lipid-lowering medications. Professor Frederick Raal explains the results of the TESLA study.
read more »
What are the current unmet needs?
Despite statins, there are significantly unmet clinical needs in cholesterol lowering treatment. Statin do not effectively treat more than 50% of people with Familial Hypercholesterolaemia (FH) and other patients have intolerable side effects, says Professor Erik Stroes.
read more »
Improving the management of the FH patient
Professor Raul Santos from Brazil says that the new therapies which inhibit PCSK9 to significantly reduce low density Lipoprotein Cholesterol (LDL-C) when given in addition to other cholesterol lowering drugs offer a very important advance in reducing cardiovascular risk in people with Familial Hypercholesterolemia (FH).
read more »
In your opinion, what are the optimum patient populations for PCSK9 monoclonal antibody therapy?
PCSK9 monoclonal antibodies offer very important new treatments to lowed low density lipoprotein cholesterol (LDL-C) in patients who cannot tolerate statins or whose LDL-C is inadequately reduced as well as those people with high LDL-C caused by Familial Hypercholesterolemia.
read more »
The role of PCSK9 inhibitors in FH
Monoclonal antibodies targeting PCSK9 have been shown to reduce low density lipoprotein cholesterol (LDL-C) by 30-40% in patients with familial hypercholesterolaemia (FH) who still have LDL receptors. Studies also show that the investigational drug, evolocumab was well tolerated, Dr Dirk Blom said.
read more »
Do the PCSK9 inhibitors have pleiotropic effects?
Experimental studies show that significant reductions in low density lipoprotein cholesterol (LDL-C) will significantly reduce inflammation which is important in Atherosclerosis (narrowing of the arteries) says Professor Erik Stroes.
read more »
